Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Access Programs

Disease Information

Descriptive Information
Brief Title † Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
Official Title † Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU
Brief Summary This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
Detailed Description PAL-003 is designed to evaluate long-term treatment of subjects who are continuing to take rAvPAL-PEG. Subjects'previous rAvPAL-PEG dosing will continue in PAL-003. In PAL- 003, each subject's dose will be adjusted as needed to attain or maintain blood Phe concentrations of 60-600 µmol/L. rAvPAL-PEG dose will be based on either a subject's weight or will be a fixed dose (subjects who have maintained blood Phe levels to 60-600 µmol/L for at least 2 consecutive weeks and who have maintained a stable rAvPAL-PEG dose for at least 2 consecutive weeks). Doses will be evaluated on an individual basis.
Study Phase Phase 2
Study Type † Interventional
Study Design †
Primary Outcome Measure † Blood Phe concentrations
Secondary Outcome Measure † Safety based on the incidence of adverse events and clinically significant changes in vital signs
Condition † Phenylketonuria
Intervention † DrugrAvPAL-PEG
Study Arms / Comparison Groups rAvPAL-PEG rAvPAL-PEG in varying doses dependent on safety and efficacy.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Drug
Estimated Enrollment † 68
Start Date † January 2010
Completion Date August 2017
Primary Completion Date May 2017
Eligibility Criteria † Inclusion Criteria: - Must have completed participation in previous rAvPAL-PEG studies. - Willing and able to provide written, signed informed consent, or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures. - Willing and able to comply with all study procedures. - Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy. - Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study. - Maintained a stable diet. - In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening. Exclusion Criteria: - Use of any investigational product (with the exception of rAvPAL-PEG) or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments. - Use of any medication that is intended to treat PKU within 14 days prior to the administration of study drug. - Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera during study participation. - A prior reaction that included systemic symptoms (eg, generalized hives, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to rAvPAL-PEG or a PEG-containing product. - Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease). - Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study. - Known hypersensitivity to rAvPAL-PEG or its excipients, including hypersensitivity reactions that necessitated early termination from previous rAvPAL-PEG studies. - Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal. - Creatinine > 1.5 times the upper limit of normal.
Gender All
Ages 16 Years - 55 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries † United States
Administrative Information
NCT ID † NCT00924703
Organization ID PAL-003
Secondary IDs ††
Responsible Party Sponsor
Study Sponsor † BioMarin Pharmaceutical
Collaborators ††
Investigators † Study Director: Celeste Decker, MD, BioMarin Pharmaceutical
Information Provided By
Verification Date January 2017
First Received Date † June 18, 2009
Last Updated Date January 30, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Abidemi Uruejoma
by Abidemi Uruejoma
by Dr. Jules Richard Kemadjou
by Dr. Jules Richard Kemadjou
Free Newsletter